The Globe and Mail reports in its Friday, Feb. 6, edition that CIBC World Markets analyst Hamir Patel has lowered his recommendation for Methanex to "neutral" from "outperformer." The Globe's David Leeder writes in the Eye On Equities column that Mr. Patel gave his share target a $6 boost to $52 (all figures U.S.). Analysts on average target the shares at $53.57. Mr. Patel says in a note: "Since late-November, Methanex has been the best-performing name across our ferts and chems coverage universe, with shares rising 35 per cent, while also outperforming North American chemical peers by 10 per cent. While we have increased confidence in the company's approach to capital allocation, as well as its ability to deliver more consistent operating performance and successfully integrate the OCI assets over the coming year, we believe that this has largely been reflected in Methanex's share price following the positive momentum over the past two months. Additionally, we see limited upside risks to realized methanol prices as macro headwinds and a tough olefins cycle weigh on demand, pressuring margins amid rising gas costs. As a result, our 2026 EBITDA estimate is 6 per cent lower than consensus."